Steven Swift, MD
Urogynecology and Reconstructive Pelvic Surgery · Charleston, SCNPI 1447366968
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,439 of the $1,860 with a category attached, or 77.4%. 8 manufacturers reported payments, led by Valencia Technologies Corporation at 31.0% of the total. Reporting peaked in 2023 at $679 and has fallen 83.3% since, to $113 in 2024.
Across 20 payments — averaging $92.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Valencia Technologies Corporation$577
- Boston Scientific$497
- Medtronic$211
- Caldera Medical, Inc$191
- Coloplast$142
- Urovant Sciences Inc$125
- plus $116 from 2 others
Across 9 payments — averaging $1122.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cook Research Incorporated$10K
What the payments were for
- Travel & lodging$42023%
- Food & beverage$1,43977%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Valencia Technologies Corporation | 4 | $577 |
| Boston Scientific | 7 | $497 |
| Medtronic | 1 | $211 |
| Caldera Medical, Inc | 2 | $191 |
| Coloplast | 1 | $142 |
| Urovant Sciences Inc | 3 | $125 |
| Axonics, Inc. | 1 | $103 |
| Sumitomo Pharma America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- eCoin Device Kit$523
- INTERSTIM$211
- Solyx SIS System$147
- AXIS$142
- OBTRYX$114
- UPSYLON$113
- Desara$110
- GEMTESA$107
- Axonics$103
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 180 | $101,160 |
| GemtesaVibegron | 87 | $43,455 |
| PremarinEstrogens, Conjugated | 59 | $19,021 |
| Estradiol | 258 | $12,783 |
| Mirabegron ErMirabegron | 24 | $10,831 |
| Solifenacin Succinate | 96 | $3,707 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 161 | $3,134 |
| Desmopressin Acetate | 99 | $2,369 |
| Trimethoprim | 43 | $2,083 |
| Oxybutynin Chloride ErOxybutynin Chloride | 37 | $1,079 |
| Ibandronate Sodium | 17 | $698 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 41 | $667 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 22 | $360 |
| Celecoxib | 13 | $341 |
| Cefdinir | 24 | $320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $13 | $43,45587 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in South Carolinaon file to place this against a meaningful peer group, so we don't.
Other urogynecology and reconstructive pelvic surgery in Charleston
- Eric RovnerCharleston$284K
- Gerald TaylorCharleston$7K
- Autumn EdenfieldCharleston$349
- Thomas GiudiceWest Columbia$418K
- Janet Harris-HicksMyrtle Beach$283K
- Jessica RuebWest Columbia$12K
- Rebecca RinkoGreenville$9K
- Ronald GlinskiFlorence$8K
- Thomas WheelerSpartanburg$6K
- Collin McKenzieWest Columbia$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.